MLL advised NASDAQ listed Masimo Corporation headquartered in California in its acquisition of a new business facility for its Swiss subsidiary in Neuchâtel.
The seller of the property is a major Swiss bank.
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.
The MLL transaction team comprised Wolfgang Müller (Picture) and Denise Läubli from the Zurich office and Jacques Johner from the Geneva office.
Law Firms: MeyerLustenberger Lachenal;
Clients: Masimo Corporation;